This compound is a nitrobenzene derivative with a complex polycyclic structure, used primarily as an intermediate in pharmaceutical research and manufacturing. It features multiple amine groups, an ether linkage, and aromatic rings, contributing to its lipophilic and polar characteristics.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Mutated EGFR-IN-1
pharmaceutical raw material
N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine
pharmaceutical intermediate
2-Bromo-4-fluorotoluene
pharmaceutical intermediate
(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol
pharmaceutical intermediate
(2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(phenylmethoxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanol
pharmaceutical intermediate
(3R,4S)-3-FLUOROOXAN-4-OL
pharmaceutical intermediate
Mobocertinib
pharmaceutical raw material
Mobocertinib succinate
pharmaceutical raw material
4-N-[2-(dimethylamino)ethyl]-2-methoxy-4-N-methyl-1-N-[4-(1-methylindol-3-yl)pyrimidin-2-yl]-5-nitrobenzene-1,4-diamine
PKEPAQKEINNCAB-UHFFFAOYSA-N
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=CC(=C(C=C4OC)N(C)CCN(C)C)[N+](=O)[O-]
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.